Abstract
Thoracic surgery evolved from procedures aimed at controlling pleural infection and tuberculosis into a technologically advanced specialty integrating oncologic resection, airway and chest wall reconstruction, transplantation, minimally invasive surgery, robotics, and data-driven care. This deliberately selective narrative historical review examines selected turning points that changed the scope or practice of the specialty and the representative pioneers associated with them. A targeted literature search prioritized original landmark reports together with contemporary evidence. The trajectory begins with drainage, collapse therapy, and solutions to open pneumothorax; continues through pneumonectomy, bronchoplastic and sublobar resection, mesothelioma surgery, pulmonary metastasectomy, screening, tracheal reconstruction, lung autotransplantation, and transplantation; and extends to VATS, uniportal and non-intubated surgery, RATS, enhanced recovery, and artificial intelligence. Across these eras, innovation repeatedly shifted from radicality toward preservation and from isolated operative technique toward multidisciplinary perioperative systems. Randomized trials have also shown that progress may require reassessing or abandoning previously accepted surgical paradigms. Thoracic surgery is therefore best understood not as a chronology of operations, but as a continuing process of redefining what is technically possible, oncologically appropriate, physiologically tolerable, and clinically valuable.
1. Introduction
Thoracic surgery is a relatively young surgical specialty, but its development spans almost a century and a half of repeated attempts to solve a small number of formidable problems: how to drain an infected pleural space without causing lethal physiological collapse; how to operate inside an open chest; how to remove diseased lung safely; how to reconstruct the airway and chest wall; how to replace an irreversibly damaged lung; and, more recently, how to reduce the biological cost of access while increasing precision [1].
The earliest milestones were driven by infection. Closed drainage, thoracoplasty, and collapse therapy emerged in an era dominated by empyema and pulmonary tuberculosis. In the early twentieth century, the open pneumothorax problem constrained intrathoracic surgery until differential-pressure systems and, later, modern positive-pressure ventilation made controlled thoracic access possible. Pulmonary resection subsequently shifted the center of gravity of the specialty from infection toward cancer, and later generations of surgeons progressively replaced radical extirpation with anatomical preservation. In parallel, bronchoscopy, mediastinoscopy, laser therapy, tracheal reconstruction, chest wall surgery, transplantation, and functional procedures expanded the field beyond pulmonary resection alone.
The late twentieth century introduced a second major transformation: the access revolution. Video-assisted thoracoscopic surgery (VATS) challenged the assumption that major thoracic operations required thoracotomy; uniportal VATS pushed this logic further; and robotic-assisted thoracic surgery (RATS) reframed minimally invasive surgery as a digital platform rather than simply a smaller incision. Artificial intelligence (AI), radiomics, surgical data science, and computer vision may now represent a further transition, in which innovation increasingly affects not only how surgeons operate but how they select, plan, predict, learn, and decide [2,3,4,5].
This narrative historical review does not aim to provide an exhaustive chronology of thoracic surgery. Instead, it identifies selected milestones that materially changed clinical practice, expanded indications, or overcame previously limiting physiological or technical barriers. It also highlights representative pioneers whose names became emblematic of these transitions, while recognizing that surgical progress is inherently collective and rarely attributable to a single individual.
2. Materials and Methods
This study was designed as a narrative historical review. A targeted search was conducted up to 29 September 2026 using PubMed/MEDLINE, supplemented by citation chaining and targeted searches of publisher archives, institutional repositories, digitized historical collections, and authoritative historical reviews. No formal language restriction was applied; historical reports in languages other than English were retained when their bibliographic identity and relevant content could be reliably verified. Digitized historical materials were additionally checked through major public collections, including the Wellcome Collection and the Medical Heritage Library/Internet Archive, together with institutional repositories when original reports were not readily indexed. Search concepts included combinations of “thoracic surgery history”, “empyema”, “Bülau drainage”, “thoracoplasty”, “tuberculosis surgery”, “collapse therapy”, “Sauerbruch”, “pneumonectomy”, “lung cancer surgery”, “lobectomy”, “segmentectomy”, “sublobar resection”, “sleeve lobectomy”, “bronchoplasty”, “mesothelioma surgery”, “MARS”, “MARS2”, “pulmonary metastasectomy”, “lung cancer screening”, “bronchoscopy”, “mediastinoscopy”, “laser bronchoscopy”, “tracheal surgery”, “carinal resection”, “lung autotransplantation”, “ex vivo lung surgery”, “chest wall surgery”, “pectus”, “thoracic outlet syndrome”, “lung transplantation”, “thoracoscopy”, “VATS”, “uniportal VATS”, “non-intubated thoracic surgery”, “spontaneous ventilation”, “robotic thoracic surgery”, “enhanced recovery after surgery”, and “artificial intelligence”.
Priority was given to original landmark reports when bibliographic details could be verified, complemented by authoritative historical papers and contemporary reviews that place older work in context. For priority-sensitive claims, original reports were checked whenever accessible and compared with independent historical syntheses; when parallel developments or uncertain priority remained, the wording was deliberately qualified rather than assigning exclusive priority. A milestone was considered eligible when it introduced a substantially new surgical principle, overcame a previously limiting physiological or technical barrier, expanded the indications of thoracic surgery, established a durable change in surgical access or technique, or materially altered patient selection and multidisciplinary care. The individuals discussed as pioneers are representative rather than exhaustive; their inclusion is intended to symbolize transitions in the specialty rather than to assign exclusive priority. Because this is a narrative historical synthesis, no formal risk-of-bias assessment, evidence grading, or quantitative pooling was performed.
3. Historical Milestones in the Evolution of Thoracic Surgery
3.1. Pleural Infection, Drainage, and the Origins of Thoracic Intervention
In the nineteenth century, pleural infection was a major surgical problem because drainage could convert a closed intrathoracic infection into an open pneumothorax, with potentially catastrophic physiological consequences. Gotthard Bülau challenged this paradigm by developing closed siphon drainage for empyema. He used the method clinically from the 1870s and published it in 1891 as “Für die Heber-Drainage bei Behandlung des Empyems” [6]. The principle—continuous drainage while preserving a closed pleural system—became foundational to modern chest drainage. Historical analysis has emphasized how far ahead of its time the concept was, preceding the better-known lessons of the First World War Empyema Commission by decades [7].
When chronic infection could not be controlled by drainage alone, operations on the chest wall attempted to obliterate persistent pleural space. Estlander and Schede became associated with progressively more extensive thoracoplasty, a strategy that appears destructive by modern standards but represented a rational response to chronic sepsis in the pre-antibiotic era. The recurring principle was already visible: the procedure was shaped by the dominant barrier of the time—in this case, uncontrolled infection and a non-expandable lung [8].
3.2. Tuberculosis and Collapse Therapy: The First Great Era of Thoracic Surgery
Pulmonary tuberculosis became one of the first diseases to generate a true thoracic surgical culture. In 1882 Carlo Forlanini proposed therapeutic artificial pneumothorax to rest the diseased lung, later reporting clinical applications and progressively establishing collapse therapy [9]. The concept was physiologically simple but clinically revolutionary: rather than removing diseased lung, one could deliberately suppress ventilation of the affected side and allow cavitary disease to heal. Artificial pneumothorax, thoracoplasty, phrenic nerve procedures, and later plombage formed a therapeutic ecosystem before effective antituberculous chemotherapy.
John Alexander helped formalize thoracic surgery as a distinct discipline through his work on pulmonary tuberculosis, including his 1925 monograph and related writings [10]. Tuberculosis also stimulated endoscopic innovation. Hans Christian Jacobaeus described thoracoscopy in 1910 [11], and thoracoscopic division of adhesions later became an adjunct to collapse therapy. In retrospect, the tuberculosis era created several elements that would reappear decades later in different form: pleural access, endoscopic visualization, lung isolation, resection, space management, and multidisciplinary selection. Contemporary surgery for localized drug-resistant tuberculosis illustrates the persistence of this relationship, although its modern role is selective and integrated with chemotherapy rather than a substitute for it [12].
3.3. Sauerbruch and the Open Pneumothorax Problem
The central physiological obstacle to early thoracic surgery was open pneumothorax. Opening the chest abolished the negative intrapleural pressure on which spontaneous ventilation depended, producing lung collapse and potentially severe cardiorespiratory instability. Ferdinand Sauerbruch addressed this problem in 1904 through differential-pressure surgery, including a negative-pressure operating chamber in which the patient’s body and surgical field were exposed to subatmospheric pressure while the head remained outside the chamber [13]. At nearly the same time, alternative positive-pressure concepts were being developed: Brauer used an overpressure approach in 1904, and Meltzer and Auer described continuous intratracheal insufflation in 1909 [14].
Sauerbruch’s solution was ingenious but technologically cumbersome. Its deeper importance lies in demonstrating that thoracic surgery required control of respiratory physiology as much as surgical dexterity. The parallel development of negative- and positive-pressure approaches shows that the essential advance was controlled ventilation rather than a single pressure strategy. Endotracheal intubation, selective lung isolation, double-lumen tubes, modern anesthesia, and intensive care eventually made pressure chambers obsolete. The transition illustrates a pattern repeated throughout thoracic history: an enabling technology may be transient, while the clinical problem it solves permanently changes the specialty. The subsequent maturation of thoracic anesthesia and perioperative care—including one-lung ventilation with double-lumen tubes and bronchial blockers, regional analgesia, postoperative intensive care, and modern rescue strategies for respiratory failure—further expanded the physiological margin of thoracic surgery; extracorporeal support extends this principle in selected contemporary high-risk procedures [15].
3.4. Experimental Pneumonectomy and the Birth of Pulmonary Resection
Pulmonary resection developed through a sequence of animal experiments, staged operations, incomplete resections, and failed clinical attempts. Early surgeons were concerned not only about hemorrhage and bronchial closure, but also about whether the circulation could tolerate pulmonary artery ligation and whether the post-pneumonectomy space could be survived. Two-stage procedures and mass ligation of the hilum preceded reliable individual control of hilar structures. Important clinical steps included Kümmell’s one-stage attempt in 1910, which ended in postoperative death, and Rudolf Nissen’s successful staged pneumonectomy in 1931; these developments are documented in Nissen’s later account and historical reviews [16,17,18]. These failures and partial successes were not peripheral to progress; they generated the physiological and technical knowledge required for successful one-stage resection.
The decisive oncologic milestone came in April 1933, when Evarts A. Graham and J. J. Singer reported successful one-stage removal of an entire lung for bronchogenic carcinoma [19]. In July 1933, William F. Rienhoff performed a successful one-stage pneumonectomy for bronchial fibrosarcoma using individual ligation of the hilar structures, an important step toward modern anatomical hilar control [17]. Graham and Singer’s operation transformed lung cancer from a disease considered largely beyond effective treatment into a potentially surgical disease. It also marked a broader transition: tuberculosis had been the dominant driver of thoracic intervention, but lung cancer would progressively become the central disease around which modern thoracic surgery organized itself.
3.5. From Pneumonectomy to Anatomical and Parenchymal-Sparing Surgery
The development of anatomical parenchymal-sparing resection began before pneumonectomy was fully standardized. Harold Brunn’s 1929 report articulated surgical principles underlying one-stage lobectomy [20]. Shenstone and Janes’ 1932 Toronto experience refined hilar control for lobectomy using a tourniquet technique [21]. Churchill and Belsey’s 1939 description of segmental pneumonectomy of the lingula for bronchiectasis became a landmark anatomical basis for segmentectomy [22]. Later historical reviews place these contributions within the evolution of anatomical pulmonary resection [23,24]. A particularly important later milestone was the development of sleeve resection. Sir Clement Price Thomas performed an early documented bronchial sleeve resection in 1947 for a bronchial adenoma and later published his experience with conservative resection of the bronchial tree in 1956 [25]. Historical accounts identify P.R. Allison’s 1952 sleeve lobectomy for bronchogenic carcinoma as an early oncologic application, marking the transition from a function-preserving solution for benign or low-grade disease to deliberate oncologic bronchoplasty [24]. What began largely as a compromise for patients considered unable to tolerate pneumonectomy evolved into the preferred operation for anatomically suitable central tumors. Bronchial sleeve lobectomy was subsequently extended to pulmonary-artery angioplasty and circumferential reconstruction, combined bronchovascular or “double-sleeve” procedures, and complex sleeve resections after induction treatment, progressively shifting the objective from avoiding pneumonectomy in fragile patients to preserving lung whenever an R0 resection can be achieved [26].
The modern debate on segmentectomy and other sublobar resections provides a second, evidence-based expression of the same historical principle. For almost three decades, the 1995 Lung Cancer Study Group randomized trial strongly reinforced lobectomy as the standard for peripheral T1N0 NSCLC because limited resection was associated with substantially more recurrence, particularly local recurrence [27]. That paradigm was reopened by contemporary imaging, screening, improved nodal staging, and the increasing detection of small peripheral tumors. JCOG0802/WJOG4607L randomized patients with peripheral clinical stage IA NSCLC ≤ 2 cm and a consolidation-to-tumor ratio > 0.5 to anatomical segmentectomy or lobectomy; 5-year overall survival was 94.3% after segmentectomy and 91.1% after lobectomy, meeting non-inferiority and showing statistical superiority for overall survival, although local relapse was higher after segmentectomy [28]. CALGB/Alliance 140503 subsequently showed that, after intraoperative confirmation of node-negative disease, sublobar resection (segmentectomy or wedge resection) was non-inferior to lobectomy for disease-free survival, with similar overall survival [29]. These trials did not simply make “less surgery” equivalent to lobectomy: they redefined the importance of tumor size and radiologic phenotype, adequate margins, rigorous hilar and mediastinal nodal assessment, and the distinction between anatomical segmentectomy and wedge resection [30,31]. The resulting historical arc is striking: from pneumonectomy as proof of operability, through lobectomy as the oncologic standard, to individualized parenchymal preservation supported by randomized evidence.
3.6. Pleural Mesothelioma: From Radical Cytoreduction to Randomized Reassessment
Pleural mesothelioma provides a particularly instructive example of how surgical innovation can move from technical escalation to evidence-driven reassessment. In the 1980s and 1990s, David Sugarbaker and colleagues developed an aggressive multimodality strategy centered on extrapleural pneumonectomy (EPP), followed by systemic therapy and radiotherapy. Their 120-patient experience helped establish macroscopic cytoreduction and multimodality treatment as a major surgical paradigm for selected patients and strongly influenced specialist practice [32]. At the same time, the procedure’s physiological cost, perioperative risk, and uncertain incremental survival benefit remained sources of controversy.
The Mesothelioma and Radical Surgery (MARS) feasibility trial represented a methodological turning point because it attempted to test EPP rather than infer benefit from selected institutional series. In its randomized comparison, EPP within trimodality therapy showed high morbidity and no evidence of survival benefit, with results suggesting possible harm, although the small feasibility design generated substantial debate [33]. The surgical field consequently shifted toward lung-sparing pleurectomy/decortication and extended pleurectomy/decortication (ePD). MARS 2 then randomized 335 patients after two chemotherapy cycles to surgery plus chemotherapy or chemotherapy alone: median survival was 19.3 versus 24.8 months, respectively, and serious adverse events were substantially more frequent in the surgical group [34]. These findings challenged the assumption that even lung-sparing macroscopic cytoreduction necessarily improves outcome. Importantly, interpretation remains contested, particularly regarding patient selection, staging, surgical quality assurance, histologic subtype, and timing of randomization [35]. Historically, mesothelioma therefore illustrates a crucial form of innovation: not only inventing more radical operations, but subjecting surgical doctrine to randomized testing and narrowing, redefining, or abandoning indications when evidence demands it.
3.7. Pulmonary Metastasectomy, Screening, and the Evolution of Oncologic Selection
Thoracic oncology also expanded beyond primary lung cancer. Pulmonary metastasectomy developed from isolated case experience into a major area of surgical oncology. The International Registry of Lung Metastases, led by Ugo Pastorino and colleagues, reported long-term outcomes in 5206 patients and provided the historical framework for selection based on completeness of resection, disease-free interval, number of metastases, and tumor biology [36]. The evidence base remains predominantly non-randomized and selection bias remains a central concern, particularly for repeat metastasectomy, but the concept helped establish surgery as a possible component of treatment for selected systemic disease [37]. Randomized evidence remains limited. In colorectal cancer, the PulMiCC trial showed that survival without metastasectomy was substantially better than historically assumed, while its small sample and imprecise estimates left the magnitude of any surgical benefit uncertain [38]. Accordingly, indications and expected benefit should be interpreted according to primary-tumor biology, systemic-therapy options, alternative local treatments including stereotactic body radiotherapy, and the evolving concept of oligometastatic disease.
Pastorino also represents another change in the surgeon’s role: from operating on detected disease to participating in earlier detection and population-level strategy. The broader randomized evidence base includes the National Lung Screening Trial (NLST) and NELSON, which demonstrated reductions in lung-cancer mortality with low-dose CT screening [39,40], while the MILD trial contributed additional long-term randomized evidence [41]. Contemporary European recommendations now integrate volumetric nodule assessment, quality assurance, and AI-assisted image analysis into screening pathways [42,43,44]. The historical implication is important: thoracic surgical innovation increasingly includes deciding when surgery should occur and for whom, not merely how it should be performed.
3.8. Bronchoscopy, Mediastinoscopy, Imaging, and Therapeutic Endoscopy
Direct visualization of the airway and mediastinum progressively changed both diagnosis and operability. Rigid bronchoscopy provided airway access long before flexible instruments expanded diagnostic reach. In 1959 Erik Carlens described cervical mediastinoscopy for inspection and biopsy of the superior mediastinum [45], creating a reproducible surgical staging procedure that became central to lung cancer management for decades. Today, endobronchial and esophageal endosonography (EBUS/EUS) are first-line invasive staging modalities in many pathways. Surgical mediastinal staging nevertheless remains relevant in selected circumstances, including negative or non-diagnostic endosonography despite a high pretest probability of mediastinal involvement, persistently suspicious imaging, incomplete sampling of relevant nodal stations, or situations in which definitive radical treatment is being considered [46].
Therapeutic bronchoscopy added another conceptual transition: thoracic treatment no longer required an external surgical incision. Nd:YAG laser therapy in the late 1970s and early 1980s enabled rapid recanalization of obstructed tracheobronchial lumens. Toty and colleagues were among the early groups using flexible-fiber YAG laser endoscopically, while Dumon and colleagues reported a large clinical experience with laser photoresection in 1982 [47,48]. Modern interventional bronchoscopy combines rigid bronchoscopy, mechanical debulking, thermal and non-thermal ablation, dilation, and stenting, and remains a central adjunct in malignant and benign central airway obstruction [49].
3.9. Chest Wall Surgery: From Oncologic Resection and Reconstruction to Minimally Invasive Remodeling
Chest wall surgery evolved along two parallel trajectories: oncologic reconstruction and correction of deformity. Mark Ravitch’s 1949 description of operative treatment for pectus excavatum established an open reconstructive framework based on cartilage resection and sternal remodeling [50]. Almost four decades later, Donald Nuss developed a radically different concept: correction without cartilage resection, using a substernal bar introduced through small lateral incisions. The first 10-year experience was published in 1998 [51].
Modern chest wall surgery incorporates individualized prosthetic reconstruction, titanium systems, three-dimensional modeling and printing, and increasingly patient-specific planning. Current pectus guidelines reflect a mature field in which structural, functional, psychosocial, and quality-of-life outcomes must all be considered [52]. The trajectory from Ravitch to Nuss and to customized 3D solutions mirrors the broader thoracic shift from large reconstructive operations toward preservation, minimal access, and personalization [53].
The oncologic trajectory of chest wall surgery is at least as old as the reconstructive one. Frederick W. Parham’s 1899 monograph on thoracic resection for tumors of the bony chest wall documented the formidable physiological consequences of entering the pleural cavity before modern anesthesia and ventilation, but also established the principle that malignant chest-wall disease could be treated by complete surgical resection [54]. In contemporary practice, wide en bloc resection with negative margins remains the central objective for primary bone and soft-tissue sarcomas. Reconstruction is not merely the final step: by restoring stability, protecting intrathoracic organs, and limiting paradoxical motion or restrictive deformity, it can enable an oncologically appropriate resection. Modern series report high rates of R0 excision with generally acceptable long-term function when surgery is performed within specialized multidisciplinary programs [55].
This principle is particularly important in children and adolescents, in whom Ewing sarcoma and related tumors account for a substantial proportion of malignant chest-wall lesions. Reconstruction must balance immediate visceral protection and respiratory mechanics against future thoracic growth, spinal development, and pulmonary function within a multimodal treatment strategy. A 30-year experience from the Istituto Nazionale dei Tumori in Milan reported Ewing-family tumors in 26 of 30 children and adolescents and included semirigid anatomical reconstruction in young patients [56]. Systematic reviews confirm that no single reconstructive strategy is universally applicable and that excessive rigidity may become a long-term liability in a growing thorax [57,58].
Reconstructive technology can therefore be considered an enabling component of oncologic surgery. Introduced clinically at the Istituto Nazionale dei Tumori in 2004, the Milan ‘rib-like’ technique was conceived as a semirigid three-dimensional reconstruction reproducing native sternocostal geometry while preserving intercostal spaces, rather than bridging the defect with a flat rigid barrier. In a 101-patient series of sternal tumors, the technique provided durable reconstruction with a low incidence of prosthesis-related complications [59]. Its broader conceptual contribution was to treat reconstruction anatomically, aiming to restore both coverage and thoracic shape and mechanics.
The same concept was extended to exceptionally radical salvage surgery. In selected patients with multiply recurrent thoracic sarcoma, thoraco-pleuro-pneumonectomy combined en bloc removal of the lung, pleura, chest wall, and diaphragm with immediate three-dimensional rib-like reconstruction [60]. Long-term follow-up documented durable local thoracic control in selected survivors while also showing progressive changes in prosthetic shape and function [61], underscoring the highly selected nature of this approach.
Chest-wall resection is also an established component of extended surgery for selected T3-T4 NSCLC with direct invasion of ribs, sternum, vertebral bodies, or adjacent soft tissues. Such procedures may require coordinated thoracic, spinal, vascular, and plastic-reconstructive strategies after induction treatment. Reconstruction is tailored to defect size and location, number of ribs removed, previous irradiation, soft-tissue availability, and the need for rigid or semirigid support [62].
The newest phase is increasingly digital and patient-specific. CT-derived three-dimensional modeling, virtual resection planning, computer-aided implant design, and additive manufacturing can link intended oncologic margins to customized titanium reconstruction [63]. This progression—from destructive thoracoplasty to anatomical, semirigid, and digitally planned reconstruction—illustrates the modern objective of reconciling oncologic radicality with preservation of thoracic form, mechanics, and long-term function.
Despite these advances, prosthesis-related infection remains a major reconstructive challenge, particularly after extensive oncologic resections performed in irradiated, necrotic, contaminated, or poorly vascularized fields. Material selection should therefore account not only for mechanical stability and patient-specific geometry, but also for biocompatibility, tissue integration, susceptibility to bacterial colonization, modularity, and the feasibility of durable vascularized soft-tissue coverage. A recent case report described reconstruction of a large full-thickness thoracic defect using a superelastic silver-containing nickel–titanium NiTi(Ag) device with antibacterial properties [64]; this approach is an illustrative reconstructive concept rather than established evidence, and requires further prospective evaluation.
3.10. The Airway Becomes Reconstructable: Tracheal and Carinal Surgery
For much of early thoracic history, extensive tracheal disease was considered unresectable because safe reconstruction appeared anatomically impossible. Hermes C. Grillo systematically defined the principles of adequate tracheal mobilization, preservation of segmental blood supply, tension reduction, tension-free primary anastomosis, and release maneuvers that made circumferential tracheal resection reproducible. His 1965 report on mediastinal and cervical tracheal resection and reconstruction became a cornerstone of modern airway surgery [65].
Tracheal and carinal resections remain among the most demanding operations in thoracic surgery, requiring precise coordination of airway management, oncologic resection, reconstruction, and perioperative care. Contemporary practice continues to build on the anatomical principles established by Grillo, emphasizing complex airway management, careful reconstruction, prevention and early recognition of anastomotic complications, and multidisciplinary perioperative care [66,67]. Minimally invasive and extracorporeal-support-assisted approaches should be regarded as highly specialized strategies for experienced centers rather than routine extensions of standard airway surgery.
3.11. Beyond Sleeve Resection: Ex Vivo Lung Surgery and Autotransplantation
Sleeve and double-sleeve reconstruction preserve parenchyma when bronchial and pulmonary-artery continuity can be restored in situ. A more extreme extension of the same principle is lung autotransplantation, developed for central tumors in which oncologically adequate resection would otherwise require pneumonectomy and conventional bronchovascular reconstruction would be impossible or under excessive tension. The early clinical experience described two complementary strategies. In some patients, an extended double-sleeve upper/middle bilobectomy left bronchial or pulmonary-artery defects too long for tension-free reconstruction; venous transposition, including implantation of the lower pulmonary vein into the proximal superior pulmonary-vein stump, was used to preserve the remaining lobe. In others, pneumonectomy was completed because the tumor crossed the fissure or involved the hilum too extensively for an in-situ sleeve; the resected lung was then transferred to a separate table, the tumor-bearing portion removed ex vivo, and the salvageable lobe replanted [68].
This strategy deliberately imports transplantation methods into oncologic resection. Modernized techniques perform pneumonectomy, separate the intact lobe on the back table, flush and cool the graft with preservation solution when prolonged ischemia is anticipated, complete ex vivo bronchovascular preparation or resection, and then reconstruct the bronchus, pulmonary artery, and venous outflow during autotransplantation [69]. The concept has also been used for salvage surgery after chemoradiation and, more recently, after neoadjuvant immunochemotherapy for advanced central NSCLC; contemporary small series report high R0-resection rates and preservation of functioning parenchyma, but with substantial technical complexity and evidence still limited to highly specialized centers [70]. Historically, lung autotransplantation is important less because it is common than because it represents the logical extreme of parenchymal preservation: even after a formal pneumonectomy, the operation can be reconceived as temporary explantation rather than irreversible loss of an entire lung. Given its technical complexity, potential complications, and the selection bias inherent in the available literature, lung autotransplantation should be regarded as a highly specialized option for carefully selected patients in centers with transplantation-level expertise, rather than as a broadly generalizable alternative to pneumonectomy.
3.12. Lung Transplantation: From Resection to Organ Replacement
A profound conceptual leap occurred when thoracic surgery moved from removing diseased lung to replacing it. In 1963 James D. Hardy and colleagues reported a landmark early human lung transplantation [71]. The recipient survived only a limited period, but technical feasibility had been demonstrated. Durable success required advances not only in surgery but in immunosuppression, infection control, donor selection, airway healing, and intensive care. The transition from technical feasibility to durable clinical treatment became evident in the 1980s, notably with the Toronto Lung Transplant Group’s report of successful unilateral lung transplantation for pulmonary fibrosis, including sustained functional recovery [72].
The modern transplantation era emerged in the 1980s and subsequently expanded to bilateral transplantation, extracorporeal membrane oxygenation as bridge or support, donation after circulatory death, extended-criteria donors, and ex vivo lung perfusion (EVLP). EVLP represents a particularly illustrative innovation because it converts the donor lung from a passive object of selection into an organ that can be assessed and potentially rehabilitated outside the body [73].
3.13. Functional Thoracic Surgery and the Thoracic Outlet
Not all defining thoracic operations are oncologic. Thoracic outlet syndrome (TOS) illustrates the specialty’s role at the interface of chest wall, vascular, and neurologic anatomy. David Roos popularized the transaxillary first-rib resection in 1966 [74]. Subsequent approaches have included supraclavicular, infraclavicular, and combined decompression tailored to neurogenic, venous, or arterial disease. Modern management emphasizes careful diagnosis and patient selection because outcomes vary substantially among TOS subtypes [75]. Sympathectomy for hyperhidrosis represents another example of function-focused thoracic surgery in which minimally invasive access transformed a previously extensive operation.
3.14. The Minimally Invasive Revolution: From Thoracoscopy to VATS Lobectomy
Thoracoscopy provides one of the most striking examples of technological recurrence in surgical history. Jacobaeus described thoracoscopy in 1910 in the context of pleural disease and tuberculosis [11]. Decades later, improvements in video technology, endoscopic staplers, energy devices, anesthesia, and imaging transformed thoracoscopy from a diagnostic or limited therapeutic technique into a platform for major anatomical resection.
Giancarlo Roviaro and colleagues were among the pioneers of major thoracoscopic pulmonary resection, reporting videoendoscopic pulmonary lobectomy for cancer in 1992 and a series of major thoracoscopic resections in 1993 [76,77]. Parallel contributions from other centers rapidly established VATS lobectomy as a reproducible operation. Over the subsequent three decades, evidence accumulated that VATS could reduce surgical trauma and facilitate recovery while maintaining oncologic principles in appropriately selected patients. The evolution of VATS is now itself a subject of historical review, illustrating how quickly a once-disruptive technique can become routine practice [78].
3.15. Uniportal VATS and the Search for Minimal Access
The internal logic of minimally invasive surgery naturally encouraged further reduction in access trauma. Single-port thoracic procedures were initially limited to minor operations, but Diego Gonzalez-Rivas and colleagues reported single-port VATS lobectomy in 2011 [79]. Uniportal VATS subsequently expanded from lobectomy to segmentectomy, sleeve resection, pulmonary artery reconstruction, and other complex procedures. Recent historical synthesis of 15 years of uniportal anatomical resection shows how rapidly the technique moved from experimental innovation to international dissemination [80].
The importance of uniportal VATS is not merely the reduction from several ports to one. It changed camera-instrument geometry, team ergonomics, teaching, and the conceptual expectation that increasingly complex thoracic surgery could be performed through a single intercostal space. It also influenced the development of uniportal robotic platforms, demonstrating again that innovations rarely remain isolated within the technology that produced them. However, the number of ports alone is not a surrogate for surgical invasiveness, oncologic quality, or patient benefit. Outcomes depend on team experience, procedural complexity, and patient selection, and a universal advantage of uniportal over multiportal VATS has not been demonstrated across all clinical settings.
3.16. Non-Intubated Thoracic Surgery: Reconsidering the Anesthetic Barrier
The evolution of non-intubated thoracic surgery creates an intriguing historical reversal. At the beginning of the twentieth century, the central challenge was to make an open chest compatible with controlled ventilation; a century later, selected surgeons and anesthesiologists began asking whether some thoracic operations required tracheal intubation and one-lung mechanical ventilation at all. Pompeo and colleagues demonstrated the feasibility of awake thoracoscopic pulmonary nodule resection under thoracic epidural anesthesia in a randomized study published in 2004 [81]. Chen and colleagues subsequently reported non-intubated thoracoscopic lobectomy for lung cancer in 2011 using regional anesthesia, vagal blockade, sedation, and spontaneous ventilation, with conversion to intubation required in a minority of patients [82].
The concept progressed from minor procedures to major anatomical resection and, importantly, to central airway surgery. In 2018, Jiang and colleagues reported spontaneous-ventilation VATS tracheal and carinal resection and reconstruction in 18 highly selected patients (14 tracheal and 4 carinal resections) without conversion to tracheal intubation, demonstrating that even operations in which the airway itself is divided can be performed without conventional cross-field ventilation in expert teams [83]. The absence of an endotracheal tube can provide an unobstructed operative field during airway anastomosis, but this advantage is inseparable from demanding anesthetic selection, cough suppression and regional/vagal blockade, rescue oxygenation strategies, and a predefined conversion plan. More recent literature describes uniportal, tubeless, and spontaneous-ventilation strategies as part of a broader effort to reduce airway instrumentation, ventilator-associated lung injury, residual neuromuscular blockade, and perioperative stress [84]. The evidence, however, remains dominated by specialized-center series rather than large randomized trials. Non-intubated surgery should therefore be viewed as a selective anesthetic-surgical strategy and a provocative extension of minimally invasive care, not as a universal replacement for modern lung isolation. These procedures require experienced surgical and anesthetic teams, effective regional analgesia and cough control, and a predefined plan for prompt intubation or conversion when necessary. Avoidance of intubation should not be considered an endpoint in itself; any proposed advantage should be demonstrated through clinically meaningful, patient-centered outcomes.
3.17. Robotic-Assisted Thoracic Surgery: From Minimally Invasive to Digital Surgery
Robotic surgery added three-dimensional visualization, articulated instruments, tremor filtration, and surgeon-console ergonomics to minimally invasive thoracic surgery. In 2002 Franca Melfi and colleagues reported early robotic thoracoscopic experience that included five lobectomies among 12 procedures, demonstrating the feasibility of telemanipulation for pulmonary resection [85]. The report was cautious, but historically important: it established a bridge between thoracoscopic surgery and digital robotic platforms.
Over two decades, RATS expanded from relatively straightforward procedures to complex lung, mediastinal, airway, and chest wall operations. Contemporary literature emphasizes both the technical capabilities and the continuing questions of cost, learning curve, access, and comparative value [86]. The broader significance of RATS is that the surgical platform itself becomes a data-generating environment capable of integrating imaging, navigation, analytics, and eventually AI. These technical advantages must be considered together with platform and disposable costs, service requirements, procedural volume, learning curves, and the need for structured training and proctorship. Three-dimensional visualization and articulated instrumentation are clear technical strengths, but they do not necessarily translate into superior clinical outcomes in every setting.
3.18. Enhanced Recovery After Surgery: Innovation Moves Beyond the Operation
A further conceptual change occurred when innovation expanded from the operation itself to the entire perioperative pathway. Enhanced Recovery After Surgery (ERAS) reframed outcome as the product of multiple coordinated interventions rather than operative technique alone: preoperative counselling and nutritional assessment, smoking cessation and selected prehabilitation, avoidance of unnecessary fasting, short-acting anesthetic strategies, regional and opioid-sparing analgesia, rational fluid management, early oral intake and mobilization, avoidance of unnecessary urinary catheters, and standardized early chest-drain removal. The ERAS Society and European Society of Thoracic Surgeons published comprehensive lung-surgery recommendations in 2019, formalizing this systems-based approach across the whole patient journey [87].
Current ERAS development is progressively challenging traditional postoperative rituals and pushing toward rapid or ambulatory pathways. In selected patients undergoing thoracoscopic anatomical resection, postoperative-day-1 discharge has been achieved with low mortality and acceptable readmission when careful selection is combined with multimodal analgesia and early drain management [88]. Chest drainage itself is being reconsidered through digital monitoring, more permissive evidence-based removal criteria, and, in carefully selected cases, omission of routine drains [89]. Contemporary analyses show that ERAS research increasingly connects minimally invasive surgery with prehabilitation, patient-reported outcomes, remote monitoring, digital follow-up, and individualized discharge planning [90]. The next step is therefore not simply a shorter hospital stay: it is a pathway in which physiological stress, tubes and catheters, opioid exposure, immobilization, and unnecessary hospital dependence are all minimized while safety and rescue capacity are preserved. Historically, this extends the meaning of thoracic innovation from making an operation possible, to making it less invasive, and finally to reducing the total burden of being a surgical patient.
3.19. Artificial Intelligence and the Emerging Era of Surgical Intelligence
AI represents a different type of innovation because it does not correspond to a single operation or instrument. Its potential extends across the entire thoracic pathway: nodule detection, radiomics, staging, risk prediction, three-dimensional reconstruction, intraoperative anatomical recognition, video analysis, performance assessment, education, and decision support. Recent reviews describe rapidly expanding applications in minimally invasive thoracic surgery and emphasize the potential convergence of AI with robotic platforms [3,4,5]. These concepts are related but distinct: radiomics extracts quantitative information from medical imaging; computer vision interprets operative images or video to recognize anatomy, instruments, and procedural steps; augmented reality superimposes registered information to support intraoperative navigation; and surgical data science integrates structured intraoperative and perioperative data for analysis, performance assessment, and decision support.
The analogy with earlier innovations is tempting but should be used cautiously. Differential-pressure chambers, staplers, VATS, and robotics addressed visible technical barriers. AI addresses informational complexity and variability. Its success will depend less on novelty than on external validation, explainability, workflow integration, data quality, cybersecurity, accountability, and demonstrable clinical benefit. History suggests that technologies endure when they solve a meaningful clinical problem more reliably than the system they replace. The principal historical milestones discussed in this review are summarized chronologically in Table 1.
Table 1.
Selected historical milestones and representative pioneers in thoracic surgery.
4. Discussion
4.1. A Recurrent Pattern of Innovation
Across very different diseases and technologies, thoracic surgery repeatedly follows a recognizable sequence: an unmet clinical need exposes a barrier; a new concept or enabling technology challenges that barrier; early experimentation produces both success and failure; validation and standardization follow; and, if the innovation proves clinically useful, it becomes incorporated into routine care. Bülau drainage addressed the physiological price of pleural drainage. Sauerbruch addressed the open pneumothorax problem. Graham demonstrated that radical pulmonary resection could be survived. Grillo made the trachea reconstructable. Hardy showed that lung replacement was technically possible. Roviaro and other VATS pioneers challenged thoracotomy as the necessary route to major pulmonary resection. Melfi and colleagues helped translate minimally invasive surgery into a robotic digital environment. AI may be entering the same cycle, but its clinical value remains to be established across many proposed applications.
4.2. From Radicality to Preservation
A second historical pattern is the progressive reduction in the physiological price paid for treatment. Thoracoplasty sacrificed chest-wall mechanics to control infection. Pneumonectomy demonstrated oncologic resectability but removed an entire lung. Later generations sought lobectomy, bronchial and bronchovascular sleeve resection, anatomical segmentectomy, and ultimately ex vivo autotransplantation to preserve functioning parenchyma whenever oncologically sound. Importantly, preservation has not followed a simple linear path: the Lung Cancer Study Group trial made lobectomy the benchmark for small NSCLC for nearly three decades, before JCOG0802 and CALGB 140503 reopened sublobar surgery under more stringent modern conditions of imaging, margins, and nodal staging [27,28,29,30,31]. Complex sleeve and autotransplantation procedures express the same principle at the technical frontier. Chest-wall oncology expresses the same shift in a different anatomical domain: modern reconstruction can permit wider oncologic margins while preserving a functional thorax, with pediatric cases adding the long-term constraint of growth. Mesothelioma adds an important counterpoint: preservation does not automatically guarantee benefit, and MARS 2 showed that even lung-sparing extended pleurectomy/decortication must justify its physiological cost through robust clinical outcomes. “Less” is therefore not inherently better; the durable innovation is the operation that achieves the necessary oncologic objective at the lowest justified biological cost.
4.3. Visionary Individuals and Collective Progress
Historical narratives naturally organize themselves around individuals because names provide memorable anchors. Yet the designation of a “first” is often more complicated than later retellings suggest. Innovations may be conceived in one institution, applied clinically in another, independently reproduced elsewhere, and only later standardized by a broader community. The pioneers emphasized in this review should therefore be understood as representative figures who crystallized major transitions. Their importance lies not only in priority, but in converting an emerging possibility into a reproducible clinical practice that others could evaluate and develop [91].
4.4. Failure as a Driver of Innovation
The conventional history of surgery overemphasizes successful first operations. Thoracic surgery, however, was built equally on operations that failed, technologies that were abandoned, and physiological assumptions that proved incorrect. Early pneumonectomy attempts, the limitations of pressure chambers, the prolonged search for durable lung transplantation, and the morbidity of radical mesothelioma surgery all illustrate this point. Randomized surgical evidence can itself become a mechanism of innovation by promoting de-implementation: MARS and MARS 2 challenged procedures that had gained authority through expert-center experience and forced the field to reconsider indications, patient selection, and the level of evidence required for high-risk surgery. Failure was therefore not the opposite of innovation; it was often the mechanism by which innovation became safer, narrower, or more scientifically accountable.
4.5. From the Individual Surgeon to the Multidisciplinary System
Another major transition concerns who, or what, produces innovation. Early thoracic surgery could be strongly identified with individual operators and their technical schools. Contemporary thoracic care is increasingly system-based. Modern lung cancer surgery depends on radiology, interventional pulmonology, pathology, molecular diagnostics, medical oncology, radiation oncology, anesthesiology, intensive care, rehabilitation, nursing, engineering, and data science. Screening and perioperative pathways extend the influence of thoracic surgery beyond the operating room. The unit of innovation is therefore shifting from the surgeon and the instrument toward the multidisciplinary pathway.
4.6. The Changing Meaning of “Minimally Invasive”
Historically, minimally invasive surgery referred primarily to smaller access incisions and avoidance of rib spreading. The concept is now broader. A procedure may be minimally invasive anatomically while still imposing substantial anesthetic, physiological, and postoperative burden. Non-intubated surgery challenges the need for routine airway instrumentation and one-lung mechanical ventilation in selected patients; ERAS pathways seek to reduce opioids, drains, catheters, fasting, immobilization, and unnecessary hospitalization. Precision staging, screening, parenchymal preservation, and individualized perioperative pathways may therefore be understood as different forms of invasiveness reduction. The modern objective is no longer merely a smaller incision, but a smaller total disruption of physiology, function, autonomy, and time spent as a patient.
4.7. Limitations
This review has several limitations. It is selective rather than exhaustive and inevitably reflects author judgment in choosing milestones and representative figures. Historical literature is incompletely indexed, terminology changes over time, and priority may be disputed when ideas developed in parallel. The review is centered mainly on European and North American surgical traditions because those sources are most readily verifiable in the indexed and digitized literature used here. Several important domains, including esophageal surgery, thoracic trauma and rib fixation, mediastinal and thymic surgery, diaphragmatic surgery, contemporary empyema management, bronchopleural fistula surgery, congenital airway surgery, and the full history of anesthesia and intensive care, are necessarily treated only indirectly. Finally, very recent technologies such as AI have not yet had sufficient time for their true historical importance to be judged. Despite these limitations, the recurrent barriers and enabling innovations identified across the selected historical trajectory are summarized in Table 2.
Table 2.
Recurrent barriers and enabling innovations in thoracic surgery.
5. Future Directions
Future thoracic innovation will probably be less defined by a single iconic operation than by convergence. Neoadjuvant systemic therapy is already changing the technical boundaries of resectability and the populations brought to surgery [92], while ex vivo lung perfusion is turning organ preservation and assessment into an active platform rather than a passive interval between procurement and implantation [93]. Robotic systems are evolving from telemanipulators into digital, data-generating platforms [94,95]; artificial intelligence and augmented-reality navigation may increasingly integrate preoperative imaging, intraoperative anatomical recognition, video analysis, and performance measurement [96,97]. At the same time, the organ preservation logic that progressed from pneumonectomy to sleeve resection and segmentectomy may extend further through complex bronchovascular reconstruction and selected lung autotransplantation. Non-intubated anesthesia, ERAS, digital drainage, remote patient-reported outcomes, and ambulatory pathways may make perioperative care itself the next major field of thoracic innovation. Patient-specific chest-wall reconstruction is another expression of this convergence, linking CT-based planning, virtual oncologic margins, additive manufacturing, biomaterials, and reconstructive surgery; in children, future solutions will also need to reconcile mechanical support with growth and long-term spinal development.
The historical record also provides a caution. Many innovations were initially promoted on technical elegance before their clinical value was fully established. Durable advances required reproducibility, appropriate indications, training, and evidence that benefits outweighed harms and costs. The same discipline should apply to complex sublobar strategies, radical mesothelioma surgery, autotransplantation, non-intubated major resection, robotics, and AI. Future progress will depend not only on what can be done, but on demonstrating which patients should receive it, in which centers, with what safeguards, and with outcomes that matter to patients.
6. Conclusions
Thoracic surgery has evolved through successive paradigm shifts rather than a linear accumulation of techniques. Pleural drainage made infection more controllable; collapse therapy created the first major thoracic therapeutic system; physiological and anesthetic advances made the open chest operable; pneumonectomy established lung cancer as surgically treatable; sleeve resection, segmentectomy, and autotransplantation progressively redefined preservation; randomized mesothelioma trials demonstrated that surgical paradigms must also be challenged and sometimes narrowed; transplantation replaced irreversible organ failure; VATS, uniportal surgery, and RATS reduced access trauma and digitalized the operative environment; ERAS pathways have reduced perioperative burden; non-intubated strategies may offer additional advantages in carefully selected patients, although their comparative benefits in major thoracic surgery remain incompletely established; and AI may increasingly support how thoracic surgeons perceive, predict, plan, and learn, provided that proposed benefits are clinically validated.
The history of thoracic surgery therefore remains unfinished: its most enduring tradition is not any single operation, instrument, or platform, but the repeated challenge of turning previously accepted limits into new clinical possibilities.
Funding
This research received no external funding.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
No new data were created or analyzed in this study. Data sharing is not applicable to this article.
Acknowledgments
Professional English editing was performed.
Conflicts of Interest
The author serves as Guest Editor of the Life Special Issue “Innovations in Thoracic Medicine: Advancements and Challenges—2nd Edition”. The author had no role in the editorial handling, reviewer selection, peer-review process, or final decision for this manuscript. No other conflict of interest relevant to this work is declared.
References
- Khaitan, P.G.; D’Amico, T.A. Milestones in thoracic surgery. J. Thorac. Cardiovasc. Surg. 2018, 155, 2779–2789. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kang, M.W. Evolution of Lung Cancer Surgery: Historical Milestones, Current Strategy, and Future Innovations. J. Chest Surg. 2025, 58, 79–84. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Uslenghi, C.; Leuzzi, G.; Solli, P.; Ferrari, M.; Prelaj, A.; Girotti, P.N.C. The role of artificial intelligence in the minimally invasive thoracic surgery: Narrative review of the last 15 years. Video-Assist. Thorac. Surg. 2026, 11, 5. [Google Scholar] [CrossRef] [Scilit]
- Aleem, M.U.; Khan, J.A.; Younes, A.; Sabbah, B.N.; Saleh, W.; Migliore, M. Enhancing Thoracic Surgery with AI: A Review of Current Practices and Emerging Trends. Curr. Oncol. 2024, 31, 6232–6244. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kutywayo, K.; Chandarana, K.; Das, I.; Rathinam, S. Artificial intelligence and machine learning in thoracic surgery—A scoping review. Clin. Surg. Oncol. 2025, 4, 100086. [Google Scholar] [CrossRef] [Scilit]
- Bülau, G. Für die Heber-Drainage bei Behandlung des Empyems. Z. Klin. Med. 1891, 18, 31–45. [Google Scholar]
- Meyer, J.A. Gotthard Bülau and closed water-seal drainage for empyema, 1875–1891. Ann. Thorac. Surg. 1989, 48, 597–599. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Miller, J.I., Jr. The history of surgery of empyema, thoracoplasty, Eloesser flap, and muscle flap transposition. Chest Surg. Clin. N. Am. 2000, 10, 45–53. [Google Scholar] [CrossRef] [Scilit]
- Forlanini, C. A contribuzione della terapia chirurgica della tisi polmonare. Ablazione del polmone? Pneumotorace artificiale? Gazz. Osp. Clin. 1882, 3, 537, 585, 601, 609, 617, 625, 641, 657, 665, 689, 705. [Google Scholar]
- Alexander, J. The Surgery of Pulmonary Tuberculosis; Lea & Febiger: Philadelphia, PA, USA, 1925. [Google Scholar]
- Jacobaeus, H.C. Ueber die Möglichkeit, die Zystoskopie bei Untersuchung seröser Höhlungen anzuwenden. Münch. Med. Wochenschr. 1910, 57, 2090–2092. [Google Scholar]
- Vashakidze, S.; Buziashvili, M.; Centis, R.; Migliori, G.B. Surgery for Active and Drug-Resistant Tuberculosis. Thorac. Surg. Clin. 2026, 36, 261–270. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Sauerbruch, F. Zur Pathologie des offenen Pneumothorax und die Grundlagen meines Verfahrens zu seiner Ausschaltung. Mitt. Grenzgeb. Med. Chir. 1904, 13, 399–482. [Google Scholar]
- Meltzer, S.J.; Auer, J. Continuous Respiration without Respiratory Movements. J. Exp. Med. 1909, 11, 622–625. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Todd, T.R. The history of ventilation in the evolution of thoracic surgery. Chest Surg. Clin. N. Am. 2000, 10, 71–82. [Google Scholar] [CrossRef] [Scilit]
- Nissen, R. Total Pneumonectomy. Ann. Thorac. Surg. 1980, 29, 390–394. [Google Scholar] [CrossRef] [Scilit]
- Brewer, L.A., III. The first pneumonectomy. Historical notes. J. Thorac. Cardiovasc. Surg. 1984, 88, 810–826. [Google Scholar] [PubMed]
- Fell, S.C. A history of pneumonectomy. Chest Surg. Clin. N. Am. 1999, 9, 267–290. [Google Scholar] [CrossRef] [Scilit]
- Graham, E.A.; Singer, J.J. Successful removal of an entire lung for carcinoma of the bronchus. JAMA 1933, 101, 1371–1374. [Google Scholar] [CrossRef] [Scilit]
- Brunn, H. Surgical Principles Underlying One-Stage Lobectomy. Arch. Surg. 1929, 18, 490–515. [Google Scholar] [CrossRef] [Scilit]
- Shenstone, N.S.; Janes, R.M. Experiences in Pulmonary Lobectomy. Can. Med. Assoc. J. 1932, 27, 138–145. [Google Scholar] [PubMed]
- Churchill, E.D.; Belsey, R. Segmental Pneumonectomy in Bronchiectasis: The Lingula Segment of the Left Upper Lobe. Ann. Surg. 1939, 109, 481–499. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Mountain, C.F. The evolution of the surgical treatment of lung cancer. Chest Surg. Clin. N. Am. 2000, 10, 83–104. [Google Scholar] [CrossRef] [Scilit]
- Kittle, C.F. The history of lobectomy and segmentectomy including sleeve resection. Chest Surg. Clin. N. Am. 2000, 10, 105–130. [Google Scholar] [CrossRef] [Scilit]
- Thomas, C.P. Conservative resection of the bronchial tree. J. R. Coll. Surg. Edinb. 1956, 1, 169–186. [Google Scholar] [PubMed]
- Voltolini, L.; Viggiano, D.; Gonfiotti, A.; Borgianni, S.; Mugnaini, G.; Salvicchi, A.; Bongiolatti, S. Complex Sleeve Lobectomy Has Lower Postoperative Major Complications Than Pneumonectomy in Patients with Centrally Located Non-Small-Cell Lung Cancer. Cancers 2024, 16, 261. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ginsberg, R.J.; Rubinstein, L.V.; Lung Cancer Study Group. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Ann. Thorac. Surg. 1995, 60, 615–623. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Saji, H.; Okada, M.; Tsuboi, M.; Nakajima, R.; Suzuki, K.; Aokage, K.; Aoki, T.; Okami, J.; Yoshino, I.; Ito, H.; et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): A multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet 2022, 399, 1607–1617. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Altorki, N.; Wang, X.; Kozono, D.; Watt, C.; Landrenau, R.; Wigle, D.; Port, J.; Jones, D.R.; Conti, M.; Ashrafi, A.S.; et al. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2023, 388, 489–498. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bertolaccini, L.; Tralongo, A.C.; Del Re, M.; Facchinetti, F.; Ferrara, R.; Franchina, T.; Graziano, P.; Malapelle, U.; Menis, J.; Passaro, A.; et al. Segmentectomy vs. Lobectomy in stage IA non-small cell lung cancer: A systematic review and meta-analysis of perioperative and survival outcomes. Lung Cancer 2024, 197, 107990. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Patel, A.J.; Lampridis, S.; Bille, A. Evolving Resection Strategies for Non-Small Cell Lung Cancers: Translating Trial Evidence to Real-World Practice. Cancers 2025, 17, 3437. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Sugarbaker, D.J.; Garcia, J.P.; Richards, W.G.; Harpole, D.H.; Healy-Baldini, E.; DeCamp, M.M.; Mentzer, S.J.; Liptay, M.J.; Strauss, G.M.; Swanson, S.J. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann. Surg. 1996, 224, 288–296. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Treasure, T.; Lang-Lazdunski, L.; Waller, D.; Bliss, J.M.; Tan, C.; Entwisle, J.; Snee, M.; O’BRien, M.; Thomas, G.; Senan, S.; et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: Clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011, 12, 763–772. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lim, E.; Waller, D.; Lau, K.; Steele, J.; Pope, A.; Ali, C.; Bilancia, R.; Keni, M.; Popat, S.; O’BRien, M.; et al. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): A phase 3 randomised controlled trial. Lancet Respir. Med. 2024, 12, 457–466. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lim, E.; Opitz, I.; Woodard, G.; Bueno, R.; de Perrot, M.; Flores, R.; Gill, R.; Jablons, D.; Pass, H. A Perspective on the MARS2 Trial. J. Thorac. Oncol. 2025, 20, 262–272. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Pastorino, U.; Buyse, M.; Friedel, G.; Ginsberg, R.J.; Girard, P.; Goldstraw, P.; Johnston, M.; McCormack, P.; Pass, H.; Putnam, J.B., Jr.; et al. Long-term results of lung metastasectomy: Prognostic analyses based on 5206 cases. J. Thorac. Cardiovasc. Surg. 1997, 113, 37–49. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bribriesco, A.C.; Bansal, P.; Subramanian, M.P.; Bograd, A.J. Reoperative Pulmonary Metastasectomy: Outcomes and Indications. Thorac. Surg. Clin. 2025, 35, 215–222. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Milosevic, M.; Edwards, J.; Tsang, D.; Dunning, J.; Shackcloth, M.; Batchelor, T.; Coonar, A.; Hasan, J.; Davidson, B.; Marchbank, A.; et al. Pulmonary Metastasectomy in Colorectal Cancer: Updated analysis of 93 randomized patients—Control survival is much better than previously assumed. Colorectal Dis. 2020, 22, 1314–1324. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- National Lung Screening Trial Research Team. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N. Engl. J. Med. 2011, 365, 395–409. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- de Koning, H.J.; van der Aalst, C.M.; de Jong, P.A.; Scholten, E.T.; Nackaerts, K.; Heuvelmans, M.A.; Lammers, J.-W.J.; Weenink, C.; Yousaf-Khan, U.; Horeweg, N.; et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N. Engl. J. Med. 2020, 382, 503–513. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Pastorino, U.; Silva, M.; Sestini, S.; Sabia, F.; Boeri, M.; Cantarutti, A.; Sverzellati, N.; Sozzi, G.; Corrao, G.; Marchianò, A. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: New confirmation of lung cancer screening efficacy. Ann. Oncol. 2019, 30, 1162–1169. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Revel, M.P.; Biederer, J.; Nair, A.; Silva, M.; Jacobs, C.; Snoeckx, A.; Prokop, M.; Prosch, H.; Parkar, A.P.; Frauenfelder, T.; et al. ESR Essentials: Lung cancer screening with low-dose CT—Practice recommendations by the European Society of Thoracic Imaging. Eur. Radiol. 2026, 36, 2064–2073. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Snoeckx, A.; Silva, M.; Prosch, H.; Biederer, J.; Frauenfelder, T.; Gleeson, F.; Jacobs, C.; Kauczor, H.-U.; Parkar, A.P.; Schaefer-Prokop, C.; et al. Lung cancer screening with low-dose CT: Definition of positive, indeterminate, and negative screen results. A nodule management recommendation from the European Society of Thoracic Imaging. Eur. Radiol. 2026, 36, 135–147. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Yip, R.; Mulshine, J.L.; Oudkerk, M.; Field, J.; Silva, M.; Yankelevitz, D.F.; Henschke, C.I. Current evidence of low-dose CT screening benefit. Eur. J. Cancer 2025, 225, 115570. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Carlens, E. Mediastinoscopy: A method for inspection and tissue biopsy in the superior mediastinum. Dis. Chest 1959, 36, 343–352. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Schwalk, A.J.; Niroula, A.; Schimmel, M. What is new in mediastinal staging? Curr. Opin. Pulm. Med. 2024, 30, 25–34. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Toty, L.; Personne, C.; Colchen, A.; Vourc’h, G. Bronchoscopic management of tracheal lesions using the neodymium yttrium aluminium garnet laser. Thorax 1981, 36, 175–178. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Dumon, J.F.; Reboud, E.; Garbe, L.; Aucomte, F.; Meric, B. Treatment of tracheobronchial lesions by laser photoresection. Chest 1982, 81, 278–284. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Samadzadeh Tabrizi, N.; Stout, P.A.; Fabian, T.; Fabian, T. The role of interventional bronchoscopy in the management of malignant central airway obstruction. Respir. Med. Case Rep. 2024, 47, 101984. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ravitch, M.M. The Operative Treatment of Pectus Excavatum. Ann. Surg. 1949, 129, 429–444. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Nuss, D.; Kelly, R.E., Jr.; Croitoru, D.P.; Katz, M.E. A 10-year review of a minimally invasive technique for the correction of pectus excavatum. J. Pediatr. Surg. 1998, 33, 545–552. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Dunning, J.; Burdett, C.; Child, A.; Davies, C.; Eastwood, D.; Goodacre, T.; Haecker, F.-M.; Kendall, S.; Kolvekar, S.; MacMahon, L.; et al. The pectus care guidelines: Best practice consensus guidelines from the joint specialist societies SCTS/MF/CWIG/BOA/BAPS for the treatment of patients with pectus abnormalities. Eur. J. Cardiothorac. Surg. 2024, 66, ezae166. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Huerta, C.T.; Alligood, D.M.; Davis, J.K.; Ramsey, W.A.; Cobler-Lichter, M.D.; Shagabayeva, L.; Delamater, J.M.; Hernandez, A.E.; Parreco, J.P.; Perez, E.A.; et al. Outcomes After Pectus Excavatum Repair: A Nationwide Comparison of Nuss Versus Ravitch Operations. J. Surg. Res. 2024, 303, 381–389. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Parham, F.W. Thoracic Resection for Tumors Growing from the Bony Wall of the Chest; Southern Surgical and Gynecological Association: New Orleans, LA, USA, 1899. [Google Scholar]
- Budacan, A.-M.; Patel, A.J.; Babu, P.; Khalil, H.; Vaiyapuri, S.; Parry, M.; Kalkat, M.S. Chest wall resection and reconstruction for primary chest wall sarcomas: Analysis of survival, predictors of outcome, and long-term functional status. J. Thorac. Cardiovasc. Surg. 2025, 169, 1120–1130.e1. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Girelli, L.; Luksch, R.; Podda, M.G.; Meazza, C.; Puma, N.; Scanagatta, P.; Pecori, E.; Diletto, B.; Galeone, C.; Massimino, M.; et al. Surgical Approach to Primary Tumors of the Chest Wall in Children and Adolescents: 30 Years of Mono-Institutional Experience. Tumori 2016, 102, 89–95. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lonnee, P.W.; Ovadja, Z.N.; Hulsker, C.C.C.; van de Sande, M.A.J.; van de Ven, C.P.; Paes, E.C. Reconstructive Strategies in Pediatric Patients after Oncological Chest Wall Resection: A Systematic Review. Eur. J. Pediatr. Surg. 2023, 33, 431–440. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Rice, D.; Barrett, S.; Lavan, N.; Daly, P.; Owens, C.; Pears, J.; Capra, M.; McGuinness, J. Evaluating the Role of Surgical Resection and Reconstruction in the Management of Ewing Sarcoma of the Chest Wall in the Paediatric Population: A Systematic Review. J. Surg. Oncol. 2025, 131, 1165–1187. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Girotti, P.; Leo, F.; Bravi, F.; Tavecchio, L.; Spano, A.; Cortinovis, U.; Nava, M.; Pastorino, U. The ‘Rib-Like’ Technique for Surgical Treatment of Sternal Tumors: Lessons Learned from 101 Consecutive Cases. Ann. Thorac. Surg. 2011, 92, 1208–1216. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Pastorino, U.; Duranti, L.; Scanagatta, P.; Leo, F.; Piccioni, F.; Collini, P.; Gronchi, A. Thoracopleuropneumonectomy with Riblike Reconstruction for Recurrent Thoracic Sarcomas. Ann. Surg. Oncol. 2014, 21, 1610–1615. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Pastorino, U.; Scanagatta, P.; Girotti, P.; Rolli, L.; Gronchi, A. Long-Term Results of Thoraco-Pleuro-Pneumonectomy (TPP) for Recurrent Thoracic Sarcomas. Ann. Surg. Oncol. 2017, 24, 551–554. [Google Scholar] [CrossRef] [Scilit] [PubMed][Green Version]
- Caso, R.; Sutton, W.; Bains, M.S.; Shahzad, F.; Jones, D.R.; Rocco, G. Chest Wall Resection and Reconstruction for T4 Non-Small Cell Lung Cancer. Semin. Thorac. Cardiovasc. Surg. 2026, 38, 153–156. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Goldsmith, I.; Bragg, T.; Jayakumar, A.; Evans, P.L. An Integrated Digital-to-Surgical Framework for Patient-Specific Chest Wall Resection and Reconstruction Using 3D-Printed Titanium Implants: Proof-of-Concept Study. npj Biomed. Innov. 2026, 3, 59. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Topolnitskiy, E.; Marchenko, E.; Chekalkin, T.; Kang, J.-H. Reconstruction of Extensive Full-Thickness Thoracic Defect Due to Giant Pleomorphic Rhabdomyosarcoma. Eur. J. Cardiothorac. Surg. 2025, 67, ezaf229. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Grillo, H.C. Circumferential resection and reconstruction of the mediastinal and cervical trachea. Ann. Surg. 1965, 162, 374–388. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lopez-Pastorini, A.; Stoelben, E. Resektionen der Trachealbifurkation. Carinal Resections. Zentralbl. Chir. 2024, 149, 298–307. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Hompe, E.; Costantino, C.L.; Mathisen, D.J.; Lanuti, M.; Panda, N. Surgical Technique of Open Tracheal, Laryngotracheal, and Carinal Resection and Reconstruction. Ann. Thorac. Surg. Short Rep. 2026; in press. [CrossRef] [Scilit]
- Zhang, G.; Liu, J.; Jiang, G.; Shen, C.; Li, M. Lung autotransplantation technique for treating central lung cancer of upper lobe. Zhonghua Wai Ke Za Zhi 2000, 38, 245–249. [Google Scholar] [PubMed]
- Nakajima, D.; Ohsumi, A.; Hamaji, M.; Chen-Yoshikawa, T.F.; Date, H. Expanded indications for auto-lung transplant technique. Gen. Thorac. Cardiovasc. Surg. 2020, 68, 828–832. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Chen, Y.; Wang, R.; Lin, D.; Pan, H.; Yang, C.; Liu, H.; Huang, W.; Fan, J.; Li, S. Lung autotransplantation for advanced central lung cancer after neoadjuvant immuno-chemotherapy: A case series study. Transl. Lung Cancer Res. 2024, 13, 2868–2879. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Hardy, J.D.; Webb, W.R.; Dalton, M.L., Jr.; Walker, G.R., Jr. Lung Homotransplantation in Man: Report of the Initial Case. JAMA 1963, 186, 1065–1074. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Toronto Lung Transplant Group. Unilateral Lung Transplantation for Pulmonary Fibrosis. N. Engl. J. Med. 1986, 314, 1140–1145. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ahmad, K.; Pluhacek, J.L.; Brown, A.W. Ex Vivo Lung Perfusion: A Review of Current and Future Application in Lung Transplantation. Pulm. Ther. 2022, 8, 149–165. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Roos, D.B. Transaxillary approach for first rib resection to relieve thoracic outlet syndrome. Ann. Surg. 1966, 163, 354–358. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Khabyeh-Hasbani, N.; Connors, K.; Buksbaum, J.R.; Koehler, S.K. Current Concepts in the Management of Neurogenic Thoracic Outlet Syndrome: A Review. Plast. Reconstr. Surg. Glob. Open 2023, 11, e4829. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Roviaro, G.C.; Rebuffat, C.; Varoli, F.; Vergani, C.; Mariani, C.; Maciocco, M. Videoendoscopic pulmonary lobectomy for cancer. Surg. Laparosc. Endosc. 1992, 2, 244–247. [Google Scholar] [PubMed]
- Roviaro, G.C.; Varoli, F.; Rebuffat, C.; Vergani, C.; D’Hoore, A.; Scalambra, S.M.; Maciocco, M.; Grignani, F. Major pulmonary resections: Pneumonectomies and lobectomies. Ann. Thorac. Surg. 1993, 56, 779–783. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Re Cecconi, E.; Mangiameli, G.; De Simone, M.; Cioffi, U.; Marulli, G.; Testori, A. Vats lobectomy for lung cancer. What has been the evolution over the time? Front. Oncol. 2024, 13, 1268362. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Gonzalez, D.; Paradela, M.; Garcia, J.; Dela Torre, M. Single-port video-assisted thoracoscopic lobectomy. Interact. Cardiovasc. Thorac. Surg. 2011, 12, 514–515. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Bassi, M.; Gonzalez-Rivas, D.; Vannucci, J.; Anile, M. Uniportal VATS for anatomical lung resection: 15 years of innovation. Front. Surg. 2026, 13, 1931138. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Pompeo, E.; Mineo, D.; Rogliani, P.; Sabato, A.F.; Mineo, T.C. Feasibility and results of awake thoracoscopic resection of solitary pulmonary nodules. Ann. Thorac. Surg. 2004, 78, 1761–1768. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Chen, J.S.; Cheng, Y.J.; Hung, M.H.; Tseng, Y.D.; Chen, K.C.; Lee, Y.C. Nonintubated thoracoscopic lobectomy for lung cancer. Ann. Surg. 2011, 254, 1038–1043. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Jiang, L.; Liu, J.; Gonzalez-Rivas, D.; Shargall, Y.; Kolb, M.; Shao, W.; Dong, Q.; Liang, L.; He, J. Thoracoscopic surgery for tracheal and carinal resection and reconstruction under spontaneous ventilation. J. Thorac. Cardiovasc. Surg. 2018, 155, 2746–2754. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Huang, K.; Zhang, Z.; Hu, T.; Qiao, L. Advances in the use of non-intubated spontaneous-ventilation video-assisted thoracoscopic surgery. Front. Surg. 2025, 12, 1584017. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Melfi, F.M.A.; Menconi, G.F.; Mariani, A.M.; Angeletti, C.A. Early experience with robotic technology for thoracoscopic surgery. Eur. J. Cardiothorac. Surg. 2002, 21, 864–868. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Odeh, A.M.; Wyant, K.; Freeman, R.K.; Abdelsattar, Z.M. Tackling complex thoracic surgical operations with robotic solutions: A narrative review. J. Thorac. Dis. 2024, 16, 1521–1536. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Batchelor, T.J.P.; Rasburn, N.J.; Abdelnour-Berchtold, E.; Brunelli, A.; Cerfolio, R.J.; Gonzalez, M.; Ljungqvist, O.; Petersen, R.H.; Popescu, W.M.; Slinger, P.D.; et al. Guidelines for enhanced recovery after lung surgery: Recommendations of the Enhanced Recovery After Surgery (ERAS®) Society and the European Society of Thoracic Surgeons (ESTS). Eur. J. Cardiothorac. Surg. 2019, 55, 91–115. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Pfeuty, K.; Rojas, D.; Iquille, J.; Lenot, B. Postoperative day 1 discharge following subxiphoid thoracoscopic anatomical lung resection: A single-centre, postoperative enhanced recovery experience. Eur. J. Cardiothorac. Surg. 2024, 65, ezae230. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Geenen, L.; Verkoulen, K.C.H.A.; Franssen, A.J.P.M.; Degens, J.H.R.J.; Hulsewé, K.W.E.; Vissers, Y.L.J.; de Loos, E.R. The evolution of chest tube management following lung cancer surgery: Many options, scarce evidence. Transl. Lung Cancer Res. 2025, 14, 3161–3169. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Liu, Y.; Zhang, T.; Gao, T.; Li, G.; Xu, G. Trends in enhanced recovery after surgery (ERAS) in thoracic surgery from a bibliometric insight. Hereditas 2025, 162, 131. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wilkins, E.W., Jr. Why history is important for thoracic surgeons. Chest Surg. Clin. N. Am. 2000, 10, 1–7. [Google Scholar] [CrossRef] [Scilit]
- Aigner, C.; Batirel, H.; Huber, R.M.; Jones, D.R.; Sihoe, A.D.L.; Štupnik, T.; Brunelli, A. Resectable non-stage IV nonsmall cell lung cancer: The surgical perspective. Eur. Respir. Rev. 2024, 33, 230195. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Nakata, K.; Alderete, I.S.; Hughes, B.A.; Hartwig, M.G. Ex vivo lung perfusion: Recent advancements and future directions. Front. Immunol. 2025, 16, 1513546. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Patel, A.J.; Yasufuku, K.; Bille, A. Robotic Thoracic Surgery: Current Landscape and Future Directions. Interdiscip. Cardiovasc. Thorac. Surg. 2026, 41, ivag009. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kuzmych, K.; Lococo, F.; Nachira, D.; Senatore, A.; Calabrese, G.; Vita, M.L.; Petracca-Ciavarella, L.; Congedo, M.T.; Meacci, E.; Margaritora, S. The evolution of robotic-assisted thoracic surgery: Current platforms, emerging technologies, and future perspectives—A narrative review. J. Robot. Surg. 2026, 20, 792. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Leivaditis, V.; Maniatopoulos, A.A.; Lausberg, H.; Mulita, F.; Papatriantafyllou, A.; Liolis, E.; Beltsios, E.; Adamou, A.; Kontodimopoulos, N.; Dahm, M. Artificial Intelligence in Thoracic Surgery: A Review Bridging Innovation and Clinical Practice for the Next Generation of Surgical Care. J. Clin. Med. 2025, 14, 2729. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Steinberga, I.; El-Hajj, V.G.; Cercenelli, L.; Romero, M.; Rodriguez-Wallberg, K.A.; Edström, E.; Elmi-Terander, A. The Use of Augmented Reality for Navigation in Minimally Invasive Abdominal and Thoracic Soft-Tissue Surgery: A Systematic Review. Sensors 2026, 26, 1962. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.